Cancer cachexia: impact, mechanisms and emerging treatments

10.1016/S1470-2045(10)70218-7

10.1016/j.clnu.2008.06.013

10.1038/nrc927

10.1017/S0029665199000439

10.1016/j.pharmthera.2008.09.009

10.1038/ncpendmet0247

10.1016/j.amjcard.2008.02.065

10.1016/j.jpainsymman.2006.05.012

10.1007/s13539-010-0002-6

10.1152/ajpcell.00154.2002

10.1097/00003465-200411000-00001

10.1016/j.jpainsymman.2006.10.015

10.1016/j.ejon.2005.09.006

10.1016/j.clnu.2007.03.011

10.1002/jcb.10601

10.1016/S0899-9007(96)00313-9

10.1002/cncr.21013

10.1016/S0149-2918(05)80001-3

10.1093/ajcn/83.6.1345

10.1007/s11605-008-0505-z

10.1007/s00520-003-0568-z

Caissie A, 2011, What QLQ-C15-PAL symptoms matter most for overall quality of life in patients with advanced cancer?, World J Oncol, 2, 166

10.1158/1078-0432.CCR-07-1147

10.1016/j.ejca.2005.07.026

10.1158/1078-0432.CCR-06-3067

10.1158/1078-0432.CCR-08-2242

10.1016/S0959-8049(97)10090-9

10.1016/j.ejca.2008.02.033

10.1016/0959-8049(96)00136-0

Goldberg RM, 1995, Pentoxifylline for treatment of cancer anorexia and cachexia? A randomized, double-blind, placebo-controlled trial, J Clin Oncol, 13, 2856, 10.1200/JCO.1995.13.11.2856

10.1097/00152192-200507000-00012

Illman J, 2005, Are inflammatory cytokines the common link between cancer-associated cachexia and depression?, J Support Oncol, 3, 37

10.1016/S1470-2045(01)00456-9

10.1016/S0006-3223(03)00413-X

10.1177/0269216307076346

10.1188/09.ONF.439-445

10.1016/j.ijnurstu.2008.10.012

10.1046/j.1365-2648.2000.01580.x

10.1016/0002-8223(94)91945-3

10.1177/0269216307077172

10.1177/082585970402000205

Evans WK, 1985, Limited impact of total parenteral nutrition on nutritional status during treatment for small cell lung cancer, Cancer Res, 45, 3347

Loprinzi CL, 1993, Body-composition changes in patients who gain weight while receiving megestrol acetate, J Clin Oncol, 11, 152, 10.1200/JCO.1993.11.1.152

10.1002/(SICI)1097-0142(19980201)82:3<553::AID-CNCR18>3.0.CO;2-0

10.1093/ajcn/83.4.735

10.1200/JCO.1987.5.1.113

Ovesen L, 1993, Effect of dietary counseling on food intake, body weight, response rate, survival, and quality of life in cancer patients undergoing chemotherapy: a prospective, randomized study, J Clin Oncol, 11, 2043, 10.1200/JCO.1993.11.10.2043

10.1097/01.mco.0000078985.18774.4b

10.1016/j.jpainsymman.2003.09.007

10.7326/0003-4819-110-9-734

10.1097/00126334-200010001-00013

10.1016/S0899-9007(01)00631-1

10.1007/PL00012350

10.1016/S1470-2045(00)00033-4

10.1200/JCO.2005.02.054

10.1007/s11739-010-0426-1

10.1002/1097-0142(197511)36:5<1888::AID-CNCR2820360546>3.0.CO;2-Y

Nielsen SS, 1980, Influence of food odors on food aversions and preferences in patients with cancer, Am J Clin Nutr, 33, 2253, 10.1093/ajcn/33.11.2253

10.1002/(SICI)1097-0142(19980515)82:10<1938::AID-CNCR18>3.0.CO;2-U

10.1097/00002820-200104000-00011

10.1016/j.ejon.2005.09.003

Wickham RS, 1999, Taste changes experienced by patients receiving chemotherapy, Oncol Nurs Forum, 26, 697

10.1188/02.CJON.73-77

Wright AL, 1981, Experimental zinc depletion and altered taste perception for NaCl in young adult males, Am J Clin Nutr, 34, 848, 10.1093/ajcn/34.5.848

Silverman JE, 1983, Zinc supplementation and taste in head and neck cancer patients undergoing radiation therapy, J Oral Med, 38, 14

10.1016/j.ijrobp.2006.10.046

10.1007/s00520-006-0061-6

10.1007/s00520-005-0015-4

10.1002/(SICI)1097-0142(19980101)82:1<42::AID-CNCR5>3.0.CO;2-M

10.2741/Tisdale

10.1172/JCI200420174

10.1016/S0140-6736(84)91929-9

Fearon KC, 1988, Influence of whole body protein turnover rate on resting energy expenditure in patients with cancer, Cancer Res, 48, 2590

Rossi Fanelli F, 1995, Tumor-induced changes in host metabolism: a possible marker of neoplastic disease, Nutrition, 11, 595

Holroyde CP, 1975, Altered glucose metabolism in metastatic carcinoma, Cancer Res, 35, 3710

10.3945/ajcn.2008.27273

10.1038/sj.bjc.6604905

10.1097/00000658-198302000-00006

Fredrix EW, 1991, Effect of different tumor types on resting energy expenditure, Cancer Res, 51, 6138

10.1001/archsurg.1986.01400070055011

10.1016/S0026-0495(97)90140-2

10.1038/bjc.1994.161

10.1159/000226793

10.1016/j.clnu.2009.07.001

10.1007/PL00012351

10.1038/nature04672

Brekel AJ S-v, 1995, Increased resting energy expenditure and weight loss are related to a systemic inflammatory response in lung cancer patients, J Clin Oncol, 13, 2600, 10.1200/JCO.1995.13.10.2600

10.1038/bjc.1996.294

Blay JY, 1992, Serum level of interleukin 6 as a prognosis factor in metastatic renal cell carcinoma, Cancer Res, 52, 3317

10.1002/1097-0142(19950415)75:8<2077::AID-CNCR2820750808>3.0.CO;2-9

10.1080/01635589809514722

10.1207/S15327914NC352_2

10.1093/jn/124.6.906

10.1152/ajpendo.2000.279.3.E707

10.1097/SPC.0b013e3283311d09

10.1016/S1072-7515(03)00382-X

10.1097/00075197-200205000-00002

Tisdale MJ, 2003, The ‘cancer cachectic factor’, Support Care Canc, 11, 73, 10.1007/s00520-002-0408-6

10.1079/NRR200488

10.1093/jnci/89.23.1763

10.1207/S15327914NC402_7

10.1093/jnci/80.8.595

Todorov PT Cariuk P McDevitt TM Coles B Fearon KCH Tisdale MJ. Characterization of a cancer cachectic factor. Nature. 1996;.

10.1074/jbc.272.19.12279

10.1046/j.1365-2168.2000.01317.x

10.1152/physiol.00019.2005

10.1054/bjoc.2001.1879

10.1038/bjc.1997.433

Watchorn TM, 2001, Proteolysis-inducing factor regulates hepatic gene expression via the transcription factors NF-(kappa)B and STAT3, FASEB J, 15, 562, 10.1096/fj.00-0534fje

10.1158/1078-0432.CCR-08-0021

10.1158/1078-0432.CCR-07-0946

10.1158/1078-0432.CCR-04-0435

10.1177/39.9.1918940

Hale LP, 2001, Zinc alpha-2-glycoprotein is expressed by malignant prostatic epithelium and may serve as a potential serum marker for prostate cancer, Clin Cancer Res, 7, 846

10.1016/0959-8049(93)90068-Q

10.1111/j.1365-2796.2011.02441.x

10.1054/bjoc.2001.1834

Tisdale MJ. Mechanisms of cancer cachexia. Physiol Rev. 2009;89:381–410.

Bandyopadhyay U, 1999, Reactive oxygen species: oxidative damage and pathogenesis, Curr Sci, 77, 658

10.1097/MCO.0b013e328302f3fe

10.1016/j.febslet.2005.02.017

10.1016/j.cellsig.2007.04.003

10.1073/pnas.0931260100

10.1016/j.biocel.2006.07.001

10.1007/s13539-011-0037-3

10.1189/jlb.1206735

10.1042/BJ20041835

10.1089/ars.2008.2220

10.1038/sj.mn.7800136

10.1172/JCI40124

10.1067/mhj.2001.114367

10.3329/jsr.v1i2.2295

Smith JK, 1989, Role of xanthine oxidase in postischemic microvascular injury in skeletal muscle, Am J Physiol, 257, H1782

10.1016/j.canlet.2004.12.005

10.1016/j.freeradbiomed.2011.04.002

10.1113/jphysiol.1997.sp021855

10.1007/s00109-003-0476-1

10.1016/S0039-6060(99)70131-5

10.1054/bjoc.2001.1696

10.1006/cyto.2002.1036

10.1097/00075197-200207000-00011

Costelli P, 2003, Mechanisms of skeletal muscle depletion in wasting syndromes: role of ATP-ubiquitin-dependent proteolysis, Curr Opin Clin Nutr Metab Care, 6, 407, 10.1097/01.mco.0000078984.18774.02

10.1083/jcb.200901052

10.1002/ijc.26298

10.1007/s10654-005-5458-x

10.1093/ije/dyl224

10.1097/PHM.0b013e31802ba53c

10.1002/cncr.10245

10.1093/oxfordjournals.eurheartj.a015229

10.1158/1078-0432.CCR-09-1525

10.1097/01.SLA.0000055225.96357.71

10.1038/sj.bjc.6602780

10.1016/j.biocel.2004.10.017

10.1038/sj.bjc.6602402

10.1152/ajpregu.2001.280.5.R1518

10.1152/physrev.00027.2001

10.1073/pnas.95.21.12602

10.1126/science.1065874

10.1096/fj.03-0610com

Muscaritoli M, 2006, Cachexia and wasting: a modern approach

10.1016/j.jbspin.2007.04.019

10.1006/bbrc.1999.1987

10.1007/s00520-005-0787-6

Wiedenmann B, 2008, A multicenter, phase II study of infliximab plus gemcitabine in pancreatic cancer cachexia, J Support Oncol, 6, 18

10.1016/j.lungcan.2009.06.020

10.1002/mus.21893

10.1042/CS20010270

10.1016/j.lungcan.2011.09.012

10.1083/jcb.201006098

10.1016/j.febslet.2010.01.056

10.1097/01.mco.0000134366.07148.2e

10.1152/ajpendo.00073.2004

10.1038/bjc.1997.463

10.1002/bjs.1800820233

10.1038/sj.bjc.6690077

Lundholm K, 1994, Anti-inflammatory treatment may prolong survival in undernourished patients with metastatic solid tumors, Cancer Res, 54, 5602

10.1038/bjc.1995.300

10.1097/SPC.0b013e32830f47e4

10.1158/1055-9965.EPI-05-0538

10.1634/theoncologist.2009-0153

10.1634/theoncologist.2009-0290

10.1016/j.clnu.2011.10.005

Burns CP, 1999, Phase I clinical study of fish oil fatty acid capsules for patients with cancer cachexia: cancer and leukemia group B study 9473, Clin Cancer Res, 5, 3942

10.1007/s11745-001-0726-4

10.1002/cncr.25933

10.1016/0899-9007(95)00078-X

Wigmore SJ, 1997, Down-regulation of the acute-phase response in patients with pancreatic cancer cachexia receiving oral eicosapentaenoic acid is mediated via suppression of interleukin-6, Clin Sci, 92, 215, 10.1042/cs0920215

10.1155/2011/601434

10.1023/A:1022970609579

10.1038/sj.bjc.6601132

10.1038/nature07959

Whitehouse AS, 2001, Mechanism of attenuation of skeletal muscle protein catabolism in cancer cachexia by eicosapentaenoic acid, Cancer Res, 61, 3604

10.1207/S15327914NC3602_6

10.1200/JCO.2004.06.024

10.1002/tox.20546

10.1038/sj.bjc.6602404

10.1042/CS19990273

10.1093/jn/129.6.1120

10.1002/cncr.20817

Tiryaki-Sönmez G, 2011, Omega-3 fatty acids and exercise: a review of their combined effects on body composition and physical performance, Biomed Hum Kinet, 3, 23, 10.2478/v10101-011-0007-4

10.1007/s13539-011-0028-4

10.1124/pr.58.1.6

10.1016/j.cardfail.2009.06.381

10.2165/00003088-200746080-00001

10.1016/0006-2952(81)90094-0

von Haehling S Morley JE Coats AJ Anker SD. Ethical guidelines for authorship and publishing in theJournal of Cachexia Sarcopenia and Muscle. J Cachexia Sarcopenia Muscle. 2010;1:7–8.